Search results
Showing 3701 to 3750 of 4138 results for patient
NICE joins international collaboration on HTA methods research
We’ve partnered with the USA-based Institute for Clinical and Economic Review (ICER) and the Canadian Drug Agency (CDA-AMC) to establish the Health Economics Methods Advisory (HEMA), a new international initiative to research and evaluate health technology assessment (HTA) methods.
NICE's guidance executive is made up of executive directors, guidance centre directors and senior team members.
Our associates help us to support high quality, safe, cost-effective prescribing and medicines optimisation.
Day-to-day decision making is the responsibility of NICE's executive team.
digital regulations service Our research work NICE International Patient access schemes and pricing agreements Our approach AI is a...
First HIV prevention injection for people unable to have daily PrEP recommended
A ground-breaking HIV-1 prevention injection has been recommended by NICE, marking a significant advance for a small group of adults and young people unable to have daily pre-exposure prophylaxis (PrEP) tablets.
NICE has been working in partnership with the London School of Economics and Political Science (LSE) to jointly develop and deliver an Executive MSc in Healthcare Decision-Making. Discover how this advanced healthcare training bridges clinical practice and system-wide decision-making through one committee member's transformative journey.
A joint NICE and NHS England meeting can help to ensure you're ready for NHS patient access and subsequent NICE appraisal
Data on the cancer recommendations made by our technology appraisal programme. Includes information on the number of positive recommendations we've made.
Our first guideline on kidney cancer recommends better use of biopsies to avoid surgery
New guidance aims to reduce variation in treatment and prevent unnecessary surgery, improving care for patients and supporting healthcare professionals.
A new model for evaluating and purchasing antimicrobials in the UK
Overview of NICE and NHS England’s pioneering subscription-style purchasing model for antimicrobials: its pilot with ceftazidime-avibactam and cefiderocol in 2022, expansion in 2024, supporting health technology assessments, downloadable guidance and procurement tools.
NICE has a key role in UK licensing and the evaluation of and access to new and innovative products for the health system.
same mission: helping practitioners and commissioners get the best care to patients fast, while ensuring value for the taxpayer. To...
Access to a range of journals, databases and other evidence-based resources for health and social care staff in England.
Learn from NICE International, part of the UK's National Institute for Health and Care Excellence, about how to improve your nation's health and wellbeing
Our modular updates framework ensures flexibility and consistency in updating our manuals and helps prioritise important updates.
NICE is committed to supporting the national agenda for achieving a sustainable health and care system.
process NICE Listens Methods research areas NICE International Patient access schemes and pricing agreements Public engagement at NICE...
We assess the efficacy and safety of interventional procedures used for treatment or diagnosis to determine whether they work well enough and are safe enough for use in the NHS.
Hundreds of people set to benefit after life-extending lung cancer treatment given green light
Targeted immunotherapy found to significantly increase overall survival rates for people with an aggressive form of lung cancer has been recommended by NICE.
Breakthrough life-extending combination treatment for advanced bladder cancer recommended by NICE
The new treatment offers hope to thousands living with advanced urothelial cancer, with clinical trials showing overall survival rates were almost twice as long compared to standard treatment.
Biggest shake-up in type 2 diabetes care in a decade announced
Millions of people are set to benefit from earlier access to newer type 2 diabetes treatments – the biggest shake-up in care for a decade – as part of NICE’s commitment to re-evaluate priority clinical pathways described in the 10-Year Health Plan for the NHS.
Recommendations in NICE’s type 2 diabetes guideline update, published today, will enhance the use of SGLT-2 inhibitors in primary care and address these health inequalities.
NICE work with the NHS, patients and carers, healthcare professionals and organisations to help put our guidance into practice.
Partner with NICE in our research work
process NICE Listens Methods research areas NICE International Patient access schemes and pricing agreements Timescales and process How...
IMI and H2020 Grant funded projects with NICE
First NICE-curated guideline announced ahead of World Duchenne Awareness Day
In the lead-up to World Duchenne Awareness Day on Sunday 7 September, we’re pleased to announce the completion of our first assessment of an externally developed clinical guideline.
Information and benefits about shared decision making. Includes links to patient decision aids.
seminars Speaking engagements Consultancy service Case studies Patient access schemes and pricing agreements Case studies Explore our...
Find out more about the types of organisations that can register to be a stakeholder at NICE.
NICE public committee meetings supports our commitment to having processes in place that are rigorous, open, and transparent.
Hypertension case finding and optimal management and lipid optimal management
medicines - Patient decision aid and user guide and data sources . Taking a statin to reduce the risk of coronary heart disease and...
Technology appraisal guidance makes recommendations on the use of new and existing medicines and other treatments within the NHS.
Guide for lay members who we've invited to sit on one of NICE's committees, panels, or groups.
From GPs, nurses and social workers, to pharmacists, physiotherapists and patients, your voice has the power to transform care across...
Patients to receive medicines 3 to 6 months faster under 10-Year Health Plan
NICE and the Medicines and Healthcare products Regulatory Agency (MHRA) have described how the 10-Year Health Plan will lead to faster medicines access for patients in the NHS in England.
Our stakeholders are involved in the development of NICE guidance and quality standards to ensure that the recommendations are relevant, practical, and meet the needs of those affected by the health or social care issues addressed.
We're at the forefront of bringing better care to people. We help practitioners and commissioners get the best care to patients, fast, while ensuring value for the taxpayer.
Final decision on cerliponase alfa for Batten disease treatment confirmed
In final draft guidance published today we've confirmed that we’re unable to recommend cerliponase alfa (also called Brineura and made by BioMarin) for routine NHS use in treating neuronal ceroid lipofuscinosis type 2 (CLN2), a rare and life-limiting form of Batten disease.
NICE Advice works closely with our system partners and industry to drive innovation into the hands of health and care professionals, to enable best practice.
Evidence standards framework (ESF) for digital health technologies
NICE standards for innovators of digital health technologies and NHS commissioners
decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or...
NICE Advice - a fee-based advisory service for pharmaceutical and healthtech companies seeking to enter the NHS market,
The NHS 2022/23 priorities and operational planning guidance, sets a lead role for Integrated Care Systems in tackling health inequalities.
Hundreds with rare inherited eye disease to benefit after NICE recommends treatment
NICE recommends idebenone for Leber's hereditary optic neuropathy following clinical evidence of vision improvement.
NICE approves first immunotherapy combination for endometrial cancer
Around 2,100 people with advanced womb cancer are set to benefit from a groundbreaking new treatment option, following our recommendation of pembrolizumab (Keytruda) in final draft guidance published today.
NICE committees are made up of people like you. They include experts in health and social care, people who use health and care services and carers. Your involvement is highly valued. We are guided by your knowledge and experience.
Learn about NICE's proportionate approach to technology appraisals, which aims to streamline the evaluation process for new health technologies, ensuring timely access to innovative treatments while maintaining rigorous standards.
In the Labonte model, health behaviours are actions individuals take that affect their health positively or negatively such as smoking, substance abuse or physical activity.